Clinical trial planning activities for a phase 2B clinical trial that compares vaxart's XBB vaccine candidate to an mrna comparator to evaluate efficacy for symptomatic and asymptomatic disease,…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50124C00002
- Awardee
-
Vaxart Biosciences Inc. UEI WS6UMD1QTBC9
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $9,271,191
Award facts
- Contract value 100% obligated
- $9,271,191.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- South San Francisco, CA 94080, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$2 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $9,271,193 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Vaxart Biosciences Inc. for clinical trial planning activities supporting a Phase 2b clinical trial comparing VaxArt's XBB vaccine candidate to an mRNA comparator, with an ultimate completion date of October 31, 2024.
The trial evaluates efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events. The contract, awarded on January 12, 2024, carried a firm fixed price structure with a ceiling value of $9,271,191. Place of performance is South San Francisco, California. This award modification de-obligates residual funding and closes out the contract.
Description
Clinical trial planning activities for a phase 2B clinical trial that compares vaxart's XBB vaccine candidate to an mrna comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse
Quick answers
Who was awarded contract 75A50124C00002?
75A50124C00002 was awarded to Vaxart Biosciences Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on January 12, 2024.
How much is contract 75A50124C00002 worth?
The government has obligated $9,271,191 on 75A50124C00002.
Was contract 75A50124C00002 competed?
The extent of competition for 75A50124C00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award